



Gene Therapy Strategies for HIV/AIDS

Guest Editor:

Dr. Grant Trobridge

Department of Pharmaceutical
Sciences, Washington State
University, Pullman, WA 99164,
USA

Deadline for manuscript
submissions:

closed (30 January 2016)

Message from the Guest Editor

Dear Colleagues,

This Special Issue “Gene Therapy Strategies for HIV/AIDS” will focus on novel approaches to treat HIV/AIDS using gene transfer.

The cure of the “Berlin patient” by transplantation of allogeneic hematopoietic stem cells has provided a proof of principle that HIV/AIDS can be treated using genetically resistant stem cells. This has led to preclinical and clinical studies exploring numerous approaches to create genetically modified hematopoietic stem cells and T cells that resist HIV infection. In addition, means to deliver transgenes encoding broadly neutralizing antibodies or antibody-fusions to muscle cells have shown great promise.

This issue will focus on novel approaches to HIV gene therapy, vector efficacy and safety, preclinical models and immunogenicity, and translation to the clinic.

Dr. Grant Trobridge

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)